Johnson & Johnson CEO, Alex Gorsky, Ordered to Attend Deposition As Risperdal Trials Restart
J&J faces two new trials related to its antipsychotic drug Risperdal for the first time since late 2019. A court ordered testimony from CEO Alex Gorsky in one. By Dave Schatz New Brunswick, NJ - Alex Gorsky, Johnson & Johnson's chairman and chief executive was ordered to provide a deposition regarding the antipsychotic drug Risperdal in a case scheduled for trial October 4. Risperdal is J&J's brand name for the powerful antipsychotic medicine risperidone, which allegedly causes gynecomastia , a condition of overdevelopment or enlargement of the breast tissue in men or boys. The p laintiffs in the case, Somerville et al v. Janssen Pharmaceuticals, Inc. et al argued that Gorsky's role in the marketing and sale of the antipsychotic medication was significant enough that he "should be compelled to provide testimony regarding his unique knowledge," according to court papers. ( Frederick Somerville, 28, a Missouri resident, sued J&J in 2017 w